MedTrace Logo

Treatment of Epiretinal Membranes With Ranibizumab

NCT01238393 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-01-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Conditions

  • Epiretinal Membrane

Interventions

DRUG

intravitreal ranibizumab

monthly injections x3 +/- 2nd series of 3

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Jeffrey Gale, MD · Queen's University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238393 on ClinicalTrials.gov